Citadel Advisors’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Citadel Advisors’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,500	Closed	-$3.99K	–	15863
2024 Q1	$3.99K	Sell	1,500 -12,400	-89%	-$30.7K	﹤0.01%	13852
2023 Q4	$32.9K	Buy	13,900 +12,000	+632%	+$21.2K	﹤0.01%	12193
2023 Q3	$2.66K	Buy	1,900 +100	+6%	+$240	﹤0.01%	13693
2023 Q2	$5.45K	Buy	1,800 +1,700	+1,700%	+$6.55K	﹤0.01%	13499
2023 Q1	$625	Hold	100	–	–	﹤0.01%	14451
2022 Q4	$610	Buy	+100	New	+$814	﹤0.01%	14618

Citadel Advisors's KNTE Position: Q2 2024 in Review

Citadel Advisors sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 214,664 shares — an estimated $571K sold.

Citadel Advisors first reported a position in KNTE in Q4 2020 and held it in 14 quarters. The position peaked at $52.3M in Q4 2020. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

Citadel Advisors reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Citadel Advisors sold 214,664 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $571K.
Citadel Advisors first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 14 quarters.
Citadel Advisors's Kinnate Biopharma Inc. Common Stock position peaked at $52.3M in Q4 2020.
0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.